Clinical Trial Update: Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial update for ABT-869 (vatalanib) in subjects with advanced Non-Small Cell Lung Cancer indicates the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ABT-869 (linifanib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED